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Abstract: Protein aggregation into amyloid fibrils is linked to multiple disorders. The understand-
ing of how natively non-harmful proteins convert to these highly cytotoxic amyloid aggregates is 
still not sufficient, with new ideas and hypotheses being presented each year. Recently it has been 
shown that more than one type of protein aggregates may co-exist in the affected tissue of patients 
suffering from amyloid-related disorders, sparking the idea that amyloid aggregates formed by one 
protein may induce another protein’s fibrillization. In this work, we examine the effect that lyso-
zyme fibrils have on insulin amyloid aggregation. We show that not only do lysozyme fibrils affect 
insulin nucleation, but they also alter the mechanism of its aggregation. 
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1. Introduction 
The event of protein or peptide aggregation into amyloid fibrils is considered to be 
the cause of multiple disorders [1–3]. Despite significant progress towards understanding 
how such insoluble and cytotoxic aggregates form, there is still no clearly defined mech-
anism of fibrillization, with new ideas or hypotheses appearing every year [4–6]. This, in 
turn, has made it extremely difficult to find an effective treatment or cure, as countless 
potential anti-amyloid compounds have failed to pass clinical trials [7,8]. Because these 
disorders affect millions of people worldwide and the number of cases is expected to in-
crease further [9,10], it is important to obtain a better comprehension of the overall mech-
anism of protein amyloid aggregation. 
Currently, the entire process can be broken down into primary nucleation, elonga-
tion, and secondary nucleation. First, the conformational change of a protein’s structure, 
leading to the formation of a stable primary aggregation center (nucleus) [11]. This is both 
the critical step in launching a cascade of protein aggregation, as well as the slowest step 
[12], which requires a plethora of events and factors to proceed in just the right way to 
achieve a stable nucleus [11]. Afterward, these primary nuclei elongate [13] by templating 
their structure [14] onto nearby homologous protein molecules and incorporating them 
into the aggregate’s structure. At later stages of aggregation, secondary processes begin 
to occur, which include fibril fragmentation and surface-catalyzed nucleation. Once fibrils 
reach a critical length, they begin to fragment and create new fibril ends [15], which are 
also capable of elongating. Surface-catalyzed nucleation (secondary nucleation) is a pro-
cess during which native protein molecules can aggregate into nuclei on the surface of 
fibrils, using it as a catalyst for their formation [16]. Additional secondary events have 
also been proposed, which take place during aggregation, such as fibril ends of one type 
of amyloid serving as templates for partial misfolding of other proteins [17]. 
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In recent years, there have been multiple reports indicating a cross-interaction be-
tween amyloid proteins [18–20]. Taking into consideration how unlikely it is for two dif-
ferent amyloid-related disorders to occur at the same time, it was hypothesized that the 
formation of a particular protein’s amyloid fibrils may be responsible for the appearance 
of a different protein’s aggregates [21]. Since fibril elongation requires the aggregate and 
native protein to have either exact or very similar amino acid sequences [22,23], this pro-
cess can be ruled out for such cases as amyloid-beta fibrils (associated with Alzheimer’s 
disease) enhancing the aggregation process of alpha-synuclein (associated with Parkin-
son’s disease) [24]. This leaves the only other available options—fibril-surface catalyzed 
nucleation (i.e., secondary nucleation) or fibril ends inducing a partial protein misfolding. 
It is still unclear whether these processes template the fibril’s conformation onto the nuclei 
or if they act as catalysts and the conformation of the resulting aggregates is dictated by 
the environmental conditions [25–27]. In the case of heterogenous seeding, the second op-
tion seems to be the most probable. 
There have been several studies displaying heterogenous cross-interactions of neu-
rodegenerative disease-related amyloid proteins. It was shown that amyloid-beta aggre-
gates are capable of inducing/enhancing the fibrilization of non-aggregated alpha-synu-
clein [24], Tau [28], and prion proteins [29]. Similarly, alpha-synuclein aggregates had a 
positive effect on Tau [30] and prion protein fibrilization [31]. It was even shown that these 
cross-interactions may lead to the inhibition of aggregation, as was the case with prion 
proteins and amyloid-beta [32]. Considering that these interactions were between neuro-
degenerative disease-related proteins, which shared a localization in vivo, it was interest-
ing to examine whether completely unrelated amyloid proteins could also have an effect 
on each other’s aggregation. For this reason, two model amyloidogenic proteins were cho-
sen—human insulin [33] and hen egg-white lysozyme [34]. Insulin is an ideal candidate 
to gather mechanistic insight into the process, as it has the ability to form fibrils with dis-
tinct conformations and replication properties at different conditions, such as pH value 
[35] or protein concentration [26]. The aggregation conditions where such conformation 
variations are visible are far from physiological (low pH value, 20% acetic acid solution, 
60 °C), however, they are necessary in order to obtain monomeric insulin [36] and have 
adequate repeatability between experiments [26]. Thus, if lysozyme fibrils have any effect 
on insulin aggregation, it will clearly reflect in the aggregation times, fibril secondary 
structure, and morphology, as well as the fluorescence intensity of an amyloid-specific 
fluorescent dye—thioflavin-T (ThT) [37,38]. In addition, both protein molecules contain 
no similarities between their amino acid sequences, negating any possible elongation 
events. 
In this work, we show that not only do lysozyme fibrils increase the rate of insulin 
nucleation, but they also have a peculiar effect on the actual mechanism of its aggregation. 
At large concentrations, lysozyme fibrils induced a similar effect as a high concentration 
of insulin protein under the tested conditions. In addition, when the initial solution con-
tained both types of fibrils, they experienced a synergistic effect, altering the aggregation 
pathway. 
2. Results 
During unseeded aggregation, in both cases where lysozyme fibrils (further referred 
to as LF) are present (Figure 1B,C), there is a noticeable initial decrease in signal intensity 
(Supplementary Material Figure S1), caused by the sample reaching 60 °C and thus reduc-
ing the fluorescence intensity of LF-bound ThT. This was followed by a slow, continuous 
increase in signal intensity (observed in the control samples), which could be the result of 
LF gradually settling at the bottom of the wells, where the fluorescence intensity was 
measured. In order to account for this effect on the overall aggregation kinetics, the control 
sample signal intensity was subtracted from the reaction solution signal. 




Figure 1. Aggregation of insulin (200 µM) in AC solution (20% acetic acid solution, containing 100 mM NaCl) with 0 µM 
(A), 2 µM (B), and 200 µM (C) lysozyme fibrils (control sample signal intensities are subtracted). The fluorescence intensity 
of ThT bound to insulin fibrils (D), normalized curve slope values (E), and aggregation half-time (t50) values (F). Fluores-
cence intensity differences, slope values, and t50 values were determined after subtracting the signal intensities of the 
control sample from the reaction sample. Different shades of green kinetic curves indicate three separate repeats. 
The average half-time (t50) value of spontaneous insulin aggregation reaction was 
~300 min (Figure 1A,F). The addition of 2 µM LF (in this case and further throughout the 
manuscript, fibril concentration refers to the concentration of protein monomers in their 
aggregated state) reduced the t50 value to ~180 min (Figure 1B,F) and increased the nor-
malized curve slope value (Figure 1E), indicating a positive effect on the rate of nucleation 
and elongation. However, the increase in the slope value was less substantial than the 
change in t50 and may be within the margin of error, as observed in additional repeats of 
the experiment (Supplementary Material Figures S2 and S3). When 200 µM LF was pre-
sent in the sample (Figure 1C), t50 was similar to conditions when no LF were present (~300 
min), and there was a decrease in the slope value (Figure 1E,F). In this case, there was also 
a massive shift in the insulin-fibril-related ThT fluorescence intensity when compared to 
the other two conditions (Figure 1D). Such a change in ThT fluorescence intensity was an 
indicator of the formation of a different insulin fibril conformation under AC conditions 
(20% acetic acid solution, containing 100 mM NaCl) [26]. Additional repeats of unseeded 
aggregation  
(Supplementary Material Figures S2 and S3) presented results with similar tendencies. 
In order to test whether fibril ends or their surface was responsible for the change in 
t50 and bound-ThT fluorescence intensity, insulin aggregation was carried out in the pres-
ence of 2 µM sonicated LF and compared against aggregation with non-sonicated LF  
(Supplementary Material Figure S4). The nearly identical t50 and slope values, as well as 
bound-ThT fluorescence intensities, indicated that the number of LF ends did not dictate 
the rate of insulin nucleation or elongation. The effect of intermediate LF concentrations 
was also examined (Supplementary Material Figure S5), however, the signal from LF-
bound ThT had a very significant effect on the overall signal intensity, as the high bound-
ThT intensity insulin conformation only appeared at high LF concentrations. 
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Seeing as the presence of LF had such a significant effect on insulin fibril formation, 
and the ThT fluorescence intensity hints at the formation of a different aggregate confor-
mation, atomic force microscopy (AFM) images were acquired to examine if there were 
any changes to fibril morphology. When there was a small concentration of LF added to 
the sample, there were no significant changes observed (Figure 2A,C), and average fibril 
height and width remained even (5 nm and 27 nm, respectively). When 200 µM of LF was 
present, it became extremely difficult to differentiate between insulin and lysozyme fi-
brils, as there was a high propensity towards cluster formation (Figure 2B,D). One aspect 
worth noting was that when insulin was aggregated with 200 µM LF, the clusters were 
significantly more massive than in the control LF samples (Figure 2B,D). Due to such clus-
ter formation, it was impossible to draw any conclusions about the effect LF had on insulin 
fibril morphology (single fibril width, height, and length could not be accurately meas-
ured), which requires an alternative method to determine whether there were any LF-
induced structural changes. 
 
Figure 2. Atomic force microscopy (AFM) images of insulin (A) and lysozyme (B) fibril control 
samples and insulin aggregated in the presence of 2 µM (C) and 200 µM (D) lysozyme fibrils. 
To determine if there were any structural differences between insulin fibrils formed 
with and without LF, each sample’s FTIR spectra were scanned (Figure 3A). Because of 
the existence of both types of aggregates, the lysozyme fibril spectrum was subtracted 
from the insulin with LF spectra as described in the Materials and Methods Section. The 
most noticeable distinction, which was observed in the second derivatives of FTIR spectra 
(Figure 3), was the additional band at 1620 cm−1, which was present only in the case when 
insulin was aggregated in the presence of 200 µM LF. As previously reported [26], such a 
band appears only in the FTIR spectra of insulin fibrils that have spontaneously formed 
at high initial protein concentrations (1.0 mM, termed high concentration fibrils—HCF) in 
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AC solution. There was also a shift in intensity at 1641 cm−1, a change which was also 
associated with the formation of HCF. This indicates that 200 µM of LF alters the aggre-
gation mechanism, leading to a different insulin fibril secondary structure, while 2 µM of 
LF has no such effect. Two additional repeats of FTIR spectra were scanned for samples 
prepared from different batches and similar tendencies were observed (Supplementary 
Material Figure S6). 
 
Figure 3. FTIR spectra of insulin aggregated in AC solution (20% acetic acid solution, containing 
100 mM NaCl) in the absence or presence of 2 µM and 200 µM lysozyme fibrils (A) and their sec-
ond derivatives (B). In cases when lysozyme fibrils were present in solution, their corresponding 
spectrum was subtracted from the mixture’s spectrum as described in the Section Materials and 
Methods. 
In order to account for the possibility that the formation of HCF iwas caused by a 
crowding effect, rather than LF themselves, insulin aggregation was carried out in the 
presence of 200 µM lysozyme monomers (Supplementary Material Figure S7). The pres-
ence of lysozyme monomers reduced the t50 value, similarly as 2 µM LF, however, they 
did not cause such an increase in ThT fluorescence intensity or changes to insulin fibril 
secondary structure  
(Supplementary Material Figure S7) as was the case with 200 µM LF. 
As lysozyme fibrils appeared to have an effect on nucleation, as well as the aggrega-
tion curve slope value (possible faster rate of elongation), seeded aggregation experiments 
were carried out in the absence or presence of 2 µM or 200 µM LF (Figure 4, Supplemen-
tary Material Figure S8). When seeded aggregation occurred in the AC solution without 
any lysozyme fibrils, we observed typical seed-concentration-dependent kinetics (Figure 
4A). The same was true when there was 2 µM of LF added to the solution (Figure 4B). In 
both cases, the overall ThT fluorescence intensity remained relatively low, however, there 
was a slightly higher end-point intensity when there was a large concentration of insulin 
seed added (Figure 4A,B,F). The average t50 values of samples without LF were higher 
throughout the entire seed concentration range when compared to the 2 µM LF samples, 
and both followed a linear trend, which converged at higher seed concentrations (Figure 
4E). The slope values were also slightly higher in the case of 2 µM LF, which was observed 
in the spontaneous aggregation experiment as well (Figure 1E). 
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Figure 4. Insulin (200 µM) seeded aggregation kinetics in the absence (A) and presence of 2 µM (B) and 200 µM (C) lyso-
zyme fibrils (control sample signal intensities are subtracted). Normalized curve slope values (D), aggregation half-time 
(t50) values (E), and fluorescence intensity of ThT bound to insulin fibrils (F). Fluorescence intensity differences, slope 
values, and t50 values were determined after subtracting the signal intensities of the control sample from the reaction 
sample. A representative curve is shown for every condition, additional repeats are available as Supplementary Material. 
However, when the samples contained 200 µM of LF, we could no longer see a clear 
trend (Figure 4C). When there was a lot of insulin seed present in the solution, the result-
ing ThT fluorescence intensity was much higher than in the case of 0 or 2 µM LF (Figure 
4F). This intensity value then began to drop until 10−3–10−4% insulin fibril concentration, 
nearly reaching the intensity of both other conditions. Afterward, it began to increase 
again, as nucleation events became dominant and the different fibril conformation dis-
played higher ThT fluorescence intensity, formed, as seen in the spontaneous aggregation 
experiment (Figure 1D). While there were no major differences observed in the aggrega-
tion curve slope values (Figure 4D), there was a noticeable distinction in the t50 values 
(Figure 4E). They were higher than in both other conditions at low initial insulin seed 
concentrations and converged in the 10−5–1% range. This t50 value dependence on initial 
seed concentration obtained a sigmoidal shape, rather than being linear, as seen in both 
the 0 µM and 2 µM LF conditions, respectively. Since this divergence appeared only when 
the initial insulin fibril concentration was low (10−5%), it is likely that LF did not have a 
prominent effect on elongation, as in such a case, we would observe lower t50 values 
throughout the entire seed concentration range. Additional repeats of seeded aggregation 
(Supplementary Material Figures S9 and S10) displayed similar tendencies. 
In order to determine the cause of the high variation in ThT fluorescence intensity 
during seeded aggregation, FTIR spectra of insulin fibrils, formed in the absence or pres-
ence of 200 µM LF at high (Figure 5A,D), intermediate (Figure 5B,E), and low (Figure 5C,F) 
initial seed concentrations were examined. When the initial insulin fibril concentration 
was 1%, the FTIR spectra of formed fibrils were similar and did not provide a clear indi-
cation of the existence of a different type of aggregate. When the seed concentration was 
10−4%, the HCF-related minima at 1620 cm−1 appeared in the sample with 200 µM LF, how-
ever, it was not as expressed as in the case of HCF, which means the sample likely con-
tained both types of aggregates. When the initial seed concentration was very low, the 
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insulin fibrils formed with 200 µM have a FTIR spectrum that was similar to the one seen 
in unseeded aggregation, which was to be expected with such a low initial fibril concen-
tration. 
 
Figure 5. FTIR spectra and their second derivatives of insulin fibrils prepared in the absence or presence of 200 µM LF, 
using an initial insulin fibril seed concentration of 1% (A,D), 10−4% (B,E), and 10−8% (C,F). 
The similarities between high initial seed concentration sample FTIR spectra (with 
minor variances due to sampling light scattering) did not explain why the resulting ThT 
fluorescence intensity was so high (Figure 4F) when such a large concentration of seed 
should effectively replicate its structure and not provide enough time for HCF nuclei to 
form. A high number of initial aggregation centers and low t50 value both led to fewer 
nucleation events, meaning the existing nuclei each had a larger portion of available mon-
omers. This would allow the formation of considerably longer fibrils than in the case of 
10−4% initial seed concentration. These longer fibrils could potentially bind more ThT mol-
ecules, as well as have a stronger interaction with LF, thus resulting in a higher bound or 
trapped ThT fluorescence intensity. In order to test this hypothesis, the high, intermediate 
and low initial fibril samples, each containing 200 µM LF, were scanned before and after 
a brief round of sonication (Supplementary Material Figure S11). On average, the 1% and 
10−8% samples experienced a larger reduction in ThT intensity than the 10−4% sample, 
however, the change percentage values were within the margin of error, and the conclu-
sion that fibril length was solely responsible for this effect cannot be confirmed. 
3. Discussion 
Considering that previously reported cases analyzed the interaction of amyloid pro-
teins that had the ability of coming into contact in vivo (alpha-synuclein, Tau, prion pro-
teins, and amyloid-beta) [24,28–32], it was interesting to examine if such amyloid cross-
interactions can occur between proteins that do not share a localization. From these re-
sults, it is clear that the presence of lysozyme fibrils has a major impact on the aggregation 
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mechanism of insulin. If we compare the fibrillization kinetics of both spontaneous and 
seeded aggregation (at extremely low initial seed concentrations) in the absence and pres-
ence of 2 µM LF, they enhance the rate of nuclei formation. Such an aggregation-promot-
ing effect, caused by amyloid fibrils, was also observed in the case of amyloid-beta [28], 
as well as alpha-synuclein [30,31]. This could be achieved by either the surface of lyso-
zyme fibrils acting as a catalyst for insulin nucleation events (fibril ends causing a partial 
misfolding of insulin can be ruled out, as a change in their number did not alter aggrega-
tion) or by creating an interface between the solution and its hydrophobic surface (inter-
face-enhanced aggregation [39]). However, both of these possible mechanisms are only 
viable at comparatively low LF concentrations, as we observe the appearance of other 
mechanism-altering effects at a high LF concentration. 
The most interesting aspect of this heterogenous interaction is the ability of lysozyme 
fibrils to induce the formation of a different insulin fibril conformation, an event that has 
not been observed in previous studies. We have recently reported that when insulin ag-
gregates in a 20% acetic acid solution, the protein’s initial concentration plays a crucial 
role in determining what type of aggregates are formed [26]. If the initial concentration is 
relatively low (0.2 mM, named low concentration fibrils—LCF), then the resulting fibrils 
are shorter, have a lower tendency towards self-association, and have a low bound-ThT 
fluorescence intensity. Conversely, when the initial protein concentration is 1.0 mM, the 
resulting fibrils are longer, have a higher tendency towards aggregate clump formation, 
and have a high bound-ThT fluorescence intensity (high concentration fibrils—HCF). 
Both of these conformations also possess differences in their FTIR spectra, with the most 
notable being a band at 1620 cm−1 in the case of HCF. When there are 200 µM of LF present, 
we observe the appearance of the HCF-like conformation, even though the concentration 
of insulin is 0.2 mM in all cases and should result in a LCF conformation. One possibility 
is that if insulin molecules associate with the surface of lysozyme fibrils, then this event 
could create a localized high-concentration area and facilitate the formation of the HCF 
conformation. Such a protein-condensing event was also reported to enhance the elonga-
tion of prion proteins [40]. This would also explain the previously mentioned effect on 
nucleation. If the effective concentration of insulin is high at certain areas, then the possi-
bility of nucleation events would also be enhanced. 
Seeded nucleation progresses without any abnormalities in the absence or presence 
of 2 µM LF, with LF reducing the t50 value and increasing the curve slope value, as was 
the case with spontaneous aggregation. However, once 200 µM of LF are added, it leads 
to extremely unusual aggregation kinetics. High initial insulin LCF seed concentrations 
result in a relatively high ThT fluorescence, which is peculiar, as such a high concentration 
of LCF insulin fibrils should replicate their structure and result in a low fluorescence in-
tensity. The effective replication of LCF was also confirmed by FTIR, which indicated that 
other factors were involved in the high ThT fluorescence. Sample sonication reduced their 
fluorescence intensity, however, the proportional decrease was not significant enough to 
indicate that fibril length is the sole reason for higher fluorescence intensity and other, 
more complex factors may be involved. Another peculiar factor is the sigmoidal shape of 
the t50 value dependence on initial seed concentration when insulin is aggregated in the 
presence of 200 µM LF. It seems that LF only has a prominent effect on nucleation, as the 
t50 values converge at 10−4%. However, this effect may be more complex than LF simply 
acting as an interface for nucleation. Considering that 2 µM LF reduces the t50 value by 
roughly 100 min, we would expect 200 µM LF to decrease it even further, but this is not 
the case. 200 µM LF actually slows down nucleation to a point where t50 values reach the 
ones observed in samples with no LF present. A possible explanation is that LF force the 
generation of HCF fibrils, which, in turn, have a lower rate of self-replication, thus in-
creasing the reaction’s t50 value. This lower rate of elongation is seen in lower slope values 
for both spontaneous nucleation and seeded aggregation with low initial fibril concentra-
tions in the presence of 200 µM LF. 
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Taking all of these results together, it appears that lysozyme fibrils can alter the mech-
anism of insulin aggregation in more ways than one. The enhanced rate of nucleation, 
formation of a new fibril conformation, and changes to the overall aggregation kinetics all 
appear to point towards the idea that lysozyme fibrils are capable of condensing non-
aggregated insulin and altering the environmental conditions, which favor the formation 
or propagation of a different insulin fibril conformation. Such synergy between two highly 
distinct proteins under non-physiological conditions may be an indicator that these cross-
interactions could be a generic feature of amyloid proteins. 
4. Materials and Methods 
4.1. Fibril Preparation 
Human recombinant insulin powder (Sigma-Aldrich, St. Louis, MO, USA, cat. No. 
91077C) was dissolved in a 20% acetic acid solution, containing 100 mM NaCl (further 
referred to as AC) to a final protein concentration of 200 µM (ε280 = 6335 M−1cm−1, M = 5808 
Da). The resulting solution was distributed to 1.5 mL test-tubes (1 mL each) and incubated 
at 60 °C for 24 h under quiescent conditions. 
Hen egg-white lysozyme powder (Sigma-Aldrich, St. Louis, MO, USA, cat. No. 
L6876) was dissolved in a 50 mM sodium phosphate buffer (pH 6.0) containing 2 M guan-
idine hydrochloride (GuHCl) to a final protein concentration of 200 µM (ε280 = 37,970 
M−1cm−1, M = 14,313 Da). The resulting solution was distributed to 1.5 mL test-tubes (1 mL 
each), each containing 2 3 mm glass-beads and incubated at 60 °C for 72 h under 600 rpm 
agitation. The resulting fibril solutions were centrifuged at 10,000× g for 30 min, the su-
pernatant was removed, and the fibril pellet was resuspended into the AC solution. This 
centrifugation and resuspension procedure was repeated 4 times. Finally, the fibrils were 
resuspended into 400 µL AC solution in each test-tube and combined to yield a solution 
with 500 µM fibril concentration (fibril concentration is the concentration of monomers in 
their aggregated state). This solution was incubated for an additional 24 h at 60 °C without 
agitation in order to negate any possible changes the different environmental conditions 
may have on the fibril structure during the following aggregation experiments. To reduce 
the possibility of reaggregation events, the fibrils were not sonicated before use. 
4.2. Aggregation Kinetics 
Human recombinant insulin powder was dissolved as previously described to a final 
concentration of 500 µM. Then, the insulin stock solution was mixed with a thioflavin-T 
(ThT) stock solution (10 mM in MilliQ water), lysozyme fibril solution, and AC solution 
to a final mixture containing 200 µM insulin, 100 µM ThT, and 0, 2, or 200 µM lysozyme 
fibrils. These mixtures were distributed to low-protein binding 96-well plates (100 µL each 
well, 3 repeats of every solution). Aggregation kinetics were tracked by monitoring ThT 
fluorescence using 440 nm excitation and 480 emission wavelengths in a ClarioStar Plus 
(BMG Labtech, Ortenberg, Germany) platereader at 60 °C with no agitation between read-
ings. 
For seeded aggregation experiments, the insulin fibril solution was sonicated for 10 
min using a Bandelin Sonopuls (Berlin, Germany) ultrasonic homogenizer (MS73 tip, 40% 
maximum power, 30 s sonication/30 s rest intervals). All the solutions for seeded aggre-
gation were prepared as described previously, additionally containing a range of insulin 
fibril concentrations (from 1% to 10−8% of total protein concentration). Control samples, 
only containing 2 or 200 µM of lysozyme fibril concentrations were monitored identically 
to subtract their signal from the combined insulin-lysozyme solution signal. 
Aggregation half-time (t50) and kinetic curve slope values were calculated by apply-
ing a linear fit to the data points ranging from 40% to 60% of normalized intensity values 
and interpolating the time at which 50% of intensity was reached. In cases when the high 
initial lysozyme fibril concentration resulted in notable fluctuations at the beginning of 
the reaction (ThT fluorescence reduction due to the sample reaching 60 °C), normalization 
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was done by omitting the initial 25 min data points. The insulin-fibril-bound ThT fluores-
cence intensity values were calculated by subtracting the fluorescence intensity at the be-
ginning of the reaction from the signal intensity at the end of the reaction (for these calcu-
lations, kinetic curves with subtracted control intensities were used). Raw kinetic data is 
available as Supplementary Material. 
4.3. Atomic Force Microscopy 
Aliquots from spontaneous aggregation fibril samples were diluted 4 times using the 
AC solution. The atomic force microscopy (AFM) images were acquired as described pre-
viously [41]. Briefly, 30 µL of each solution was distributed on freshly-cleaved mica, incu-
bated for 1 min, gently washed with MilliQ water, and air-dried. 1024 × 1024 resolution 
AFM images were acquired using a Dimension Icon (Bruker, Billerica, MA, USA) atomic 
force microscope in tapping mode (3 images for every condition). The AFM images were 
flattened using Gwyddion 2.5.5 software. Fibril height and width were determined by 
tracing perpendicular to the fibril’s axis (only non-clumped fibrils or fibril ends were used 
in order to acquire accurate, single-fibril data). A total of 200 traces were obtained from 
all 3 AFM images for each sample. 
4.4. Fourier-Transform Infrared Spectroscopy 
FTIR spectra of each aggregation sample were acquired as described previously [41]. 
Briefly, the fibril solutions were centrifuged for 30 min at 10,000× g, then the supernatant 
was removed, and the fibril pellets were resuspended in 500 µL D2O, containing 200 mM 
NaCl (higher ionic strength result in higher fibril self-association and improve sedimen-
tation [42]. This centrifugation and resuspension procedure was repeated 4 times. Finally, 
the fibrils were resuspended in 150 µL of D2O (without NaCl), sonicated for 30 s (MS72 
tip, 20% power). For each sample, 256 interferograms were obtained using a Vertex 80v 
(Bruker, Billerica, MA, USA) IR spectrometer at room temperature under near-vacuum 
conditions. FTIR spectra were analyzed using GRAMS software. In each case, both the 
D2O and the lysozyme fibril (where necessary) spectra were subtracted. Lysozyme fibril 
spectrum subtraction factor was based on the portion of peptide bonds related to each 
protein (factor was set to 0.72 for samples with 200 µM LF and 0.025 for 2 µM LF). Raw 
FTIR data is available as Supplementary Material. 
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